{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T11:40:43Z","timestamp":1792669243803,"version":"4.5.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020152","name":"Madrigal Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020152","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jhep.2026.08.037","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:36:50Z","timestamp":1791243410000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effects of MASH risk genotypes on resmetirom efficacy in patients with MASH and fibrosis"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4082-3178","authenticated-orcid":false,"given":"Naga P.","family":"Chalasani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Taub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Mogg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Labriola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul C.","family":"Camacho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3953-7572","authenticated-orcid":false,"given":"Hang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9518-0088","authenticated-orcid":false,"given":"Quentin M.","family":"Anstee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2026.08.037_bib1","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2026.08.037_bib2","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMra1503519","article-title":"Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis","volume":"377","author":"Diehl","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2026.08.037_bib3","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.jacc.2018.11.050","article-title":"Nonalcoholic fatty liver disease and the Heart: JACC State-of-the-Art review","volume":"73","author":"Stahl","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jhep.2026.08.037_bib4","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver fibrosis, but No other histologic features, is associated with Long-term outcomes of patients with nonalcoholic fatty liver disease","volume":"149","author":"Angulo","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2026.08.037_bib5","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/hep.29085","article-title":"Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis","volume":"65","author":"Dulai","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2026.08.037_bib6","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.jhep.2017.07.027","article-title":"Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD","volume":"67","author":"Hagstrom","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.08.037_bib7","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1038\/s41395-018-0088-6","article-title":"NASH leading cause of liver transplant in Women: Updated analysis of indications for liver transplant and ethnic and Gender Variances","volume":"113","author":"Noureddin","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2026.08.037_bib8","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/hep.30254","article-title":"Burden of Illness and economic model for patients with nonalcoholic steatohepatitis in the United States","volume":"69","author":"Younossi","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2026.08.037_bib9","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.54707","article-title":"Estimated burden of metabolic dysfunction-associated steatotic liver disease in US adults, 2020 to 2050","volume":"8","author":"Le","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jhep.2026.08.037_bib10","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1053\/j.gastro.2020.01.053","article-title":"Toward genetic prediction of nonalcoholic fatty liver disease Trajectories: PNPLA3 and beyond","volume":"158","author":"Krawczyk","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2026.08.037_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101111","article-title":"Genetic and epigenetic factors determining NAFLD risk","volume":"50","author":"Jonas","year":"2021","journal-title":"Mol Metab"},{"key":"10.1016\/j.jhep.2026.08.037_bib12","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.jhep.2023.05.007","article-title":"Therapeutic opportunities for the treatment of NASH with genetically validated targets","volume":"79","author":"Linden","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.08.037_bib13","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/ng.257","article-title":"Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease","volume":"40","author":"Romeo","year":"2008","journal-title":"Nat Genet"},{"key":"10.1016\/j.jhep.2026.08.037_bib14","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/MEG.0000000000000061","article-title":"Pi\u2217Z heterozygous alpha-1 antitrypsin states accelerate parenchymal but not biliary cirrhosis","volume":"26","author":"Cacciottolo","year":"2014","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2026.08.037_bib15","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/ng.2901","article-title":"Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease","volume":"46","author":"Kozlitina","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.jhep.2026.08.037_bib16","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1053\/j.gastro.2016.01.032","article-title":"The MBOAT7-TMC4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of European descent","volume":"150","author":"Mancina","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2026.08.037_bib17","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1056\/NEJMoa1712191","article-title":"A protein-Truncating HSD17B13 variant and protection from Chronic liver disease","volume":"378","author":"Abul-Husn","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2026.08.037_bib18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1008629","article-title":"A missense variant in Mitochondrial Amidoxime Reducing Component 1 gene and protection against liver disease","volume":"16","author":"Emdin","year":"2020","journal-title":"Plos Genet"},{"key":"10.1016\/j.jhep.2026.08.037_bib19","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.medj.2021.04.011","article-title":"A genome-first approach to mortality and metabolic phenotypes in MTARC1 p.Ala165Thr (rs2642438) heterozygotes and homozygotes","volume":"2","author":"Schneider","year":"2021","journal-title":"Med"},{"key":"10.1016\/j.jhep.2026.08.037_bib20","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3389\/fmed.2020.00331","article-title":"Selective thyroid hormone receptor-beta (TRbeta) agonists: new Perspectives for the treatment of metabolic and Neurodegenerative Disorders","volume":"7","author":"Saponaro","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jhep.2026.08.037_bib21","doi-asserted-by":"crossref","first-page":"16158","DOI":"10.3390\/ijms160716158","article-title":"Thyroid hormone mediated Modulation of Energy Expenditure","volume":"16","author":"Vaitkus","year":"2015","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jhep.2026.08.037_bib22","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1089\/thy.2021.0621","article-title":"Thyroid hormone decreases hepatic steatosis, inflammation, and fibrosis in a dietary Mouse model of nonalcoholic steatohepatitis","volume":"32","author":"Zhou","year":"2022","journal-title":"Thyroid"},{"key":"10.1016\/j.jhep.2026.08.037_bib23","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1021\/jm4019299","article-title":"2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptor beta agonist in clinical trials for the treatment of dyslipidemia","volume":"57","author":"Kelly","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.jhep.2026.08.037_bib24","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2026.08.037_bib25","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.atherosclerosis.2013.07.056","article-title":"Lipid lowering in healthy volunteers treated with multiple doses of MGL-3196, a liver-targeted thyroid hormone receptor-beta agonist","volume":"230","author":"Taub","year":"2013","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jhep.2026.08.037_bib26","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.jacc.2022.01.023","article-title":"Resmetirom (MGL-3196) in patients with heterozygous familial hypercholesterolemia","volume":"79","author":"Hovingh","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jhep.2026.08.037_bib27","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1038\/s41591-023-02603-1","article-title":"Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial","volume":"29","author":"Harrison","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2026.08.037_bib28","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","article-title":"Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"394","author":"Harrison","year":"2019","journal-title":"The Lancet"},{"key":"10.1016\/j.jhep.2026.08.037_bib29","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/hep.31032","article-title":"Patatin-like phospholipase domain-containing protein 3 I148M and liver fat and fibrosis scores Predict liver disease mortality in the U.S. Population","volume":"71","author":"Unalp-Arida","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2026.08.037_bib30","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1002\/hep.31113","article-title":"PNPLA3 genotype and risk of liver and all-cause mortality","volume":"71","author":"Stender","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2026.08.037_bib31","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/hep.31238","article-title":"Combined effect of PNPLA3, TM6SF2, and HSD17B13 variants on risk of cirrhosis and hepatocellular carcinoma in the general population","volume":"72","author":"Gellert-Kristensen","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2026.08.037_bib32","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/liv.14387","article-title":"Association of HSD17B13 rs72613567:TA with non-alcoholic fatty liver disease in Hispanics\/Latinos","volume":"40","author":"Kallwitz","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2026.08.037_bib33","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1464-5491.2006.01858.x","article-title":"Metabolic syndrome--a new world-wide definition. A consensus statement from the International diabetes Federation","volume":"23","author":"Alberti","year":"2006","journal-title":"Diabet Med"},{"key":"10.1016\/j.jhep.2026.08.037_bib34","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.jhep.2021.10.013","article-title":"Distinct contributions of metabolic dysfunction and genetic risk factors in the pathogenesis of non-alcoholic fatty liver disease","volume":"76","author":"Luukkonen","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.08.037_bib35","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1002\/hep.24283","article-title":"Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease","volume":"53","author":"Sookoian","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2026.08.037_bib36","doi-asserted-by":"crossref","first-page":"9284","DOI":"10.1038\/srep09284","article-title":"Association between patatin-like phospholipase domain containing 3 gene (PNPLA3) polymorphisms and nonalcoholic fatty liver disease: a HuGE review and meta-analysis","volume":"5","author":"Xu","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhep.2026.08.037_bib37","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1002\/hep.23759","article-title":"The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease","volume":"52","author":"Rotman","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2026.08.037_bib38","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1194\/jlr.P089953","article-title":"Splice variant rs72613567 prevents worst histologic outcomes in patients with nonalcoholic fatty liver disease","volume":"60","author":"Pirola","year":"2019","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jhep.2026.08.037_bib39","doi-asserted-by":"crossref","first-page":"4309","DOI":"10.1038\/ncomms5309","article-title":"TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease","volume":"5","author":"Liu","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhep.2026.08.037_bib40","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/hep.27490","article-title":"Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease","volume":"61","author":"Dongiovanni","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2026.08.037_bib41","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1111\/apt.70382","article-title":"Effects of resmetirom on metabolic-dysfunction associated steatohepatitis in patients with weight Loss and\/or diabetes Taking Glucagon-like Peptide-1 receptor agonists and other diabetes Therapies: a secondary analysis of the MAESTRO-NASH trial","volume":"62","author":"Noureddin","year":"2025","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2026.08.037_bib42","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.jcmgh.2021.11.007","article-title":"TM6SF2\/PNPLA3\/MBOAT7 Loss-of-function genetic variants impact on NAFLD development and progression both in patients and in in Vitro models","volume":"13","author":"Longo","year":"2022","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2026.08.037_bib43","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1089\/thy.2018.0664","article-title":"Nonalcoholic fatty liver disease and hypercholesterolemia: Roles of thyroid hormones, Metabolites, and agonists","volume":"29","author":"Sinha","year":"2019","journal-title":"Thyroid"},{"key":"10.1016\/j.jhep.2026.08.037_bib44","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.jhep.2024.10.048","article-title":"PNPLA3(148M) is a gain-of-function mutation that promotes hepatic steatosis by inhibiting ATGL-mediated triglyceride hydrolysis","volume":"82","author":"Wang","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.08.037_bib45","series-title":"American association for the study of liver diseases","article-title":"Impact of PNPLA3 rs738409 variant on the response to tirzepatide versus placebo for the treatment of non-cirrhotic MASH. The Liver Meeting","year":"2024"},{"key":"10.1016\/j.jhep.2026.08.037_bib46","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1097\/HEP.0000000000001792","article-title":"Consistent efficacy of efruxifermin across PNPLA3 genotypes in phase 2b trials in MASH","volume":"84","author":"Chalasani","year":"2026","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2026.08.037_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2026.03.021","article-title":"Quantitative regression of qFibrosis with resmetirom: exploratory histologic endpoints from the MAESTRO-NASH phase III clinical trial","author":"Schattenberg","year":"2026","journal-title":"J Hepatol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827826029107?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827826029107?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T11:07:07Z","timestamp":1792667227000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827826029107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":47,"alternative-id":["S0168827826029107"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2026.08.037","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of MASH risk genotypes on resmetirom efficacy in patients with MASH and fibrosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2026.08.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.","name":"copyright","label":"Copyright"}]}}